0001093557-24-000133.txt : 20240620 0001093557-24-000133.hdr.sgml : 20240620 20240620165015 ACCESSION NUMBER: 0001093557-24-000133 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240617 FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FOLETTA MARK G CENTRAL INDEX KEY: 0001236389 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 241057183 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-06-17 0 0001093557 DEXCOM INC DXCM 0001236389 FOLETTA MARK G 6340 SEQUENCE DRIVE SAN DIEGO CA 92121 1 0 0 0 1 Common Stock 2024-06-17 4 S 0 7 115.18 D 62391 I by Trust Common Stock 2024-06-17 4 S 0 2212 117.1607 D 60179 I by Trust Common Stock 2024-06-17 4 S 0 475 117.7717 D 59704 I by Trust Common Stock 2024-06-18 4 S 0 3007 116.7493 D 56697 I by Trust Common Stock 2024-06-18 4 S 0 299 117.2455 D 56398 I by Trust Common Stock 2973 D On March 15, 2024, the Foletta Family Trust DTD 1/30/15 (the ?Trust?) adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. This transaction was executed in multiple trades at prices ranging from $116.76 to $117.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $117.61 to $117.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $116.265 to $117.195. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. This transaction was executed in multiple trades at prices ranging from $117.235 to $117.26. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. By: /s/ Jereme M Sylvain For: Mark G Foletta 2024-06-20